Freedom of Information request on the product Alemtuzumab (FOI 22/771)
Published 27 March 2023
漏 Crown copyright 2023
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: [email protected].
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at /government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-27-june-2022/freedom-of-information-request-on-the-product-alemtuzumab-foi-22771
FOI 22/771
30th June 2022
Dear
Alemtuzumab is authorised as Lemtrada for multiple sclerosis.聽
Alemtuzumab was previously authorised as MabCampath for B-cell chronic lymphocytic leukaemia but the licence was withdrawn in 2012.聽 The link below provides further information:
Information regarding the previously authorised use of MabCampath is available at the link below
Use of alemtuzumab in transplant patients would be unlicensed use.
Kind regards,
FOI Team
Vigilance and Risk Management of Medicines Division